Exabis Library
Welcome to the e-CCO Library!
DOP049: Combination therapy of cyclosporine and vedolizumab is effective and safe for severe, steroid-resistant ulcerative colitis patients: A prospective study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP049: Efficacy and safety of golimumab induction
for moderate-to-severe ulcerative colitis in
the United Kingdom: results from the
GO-COLITIS study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP049: Inflammatory dyskinesis: defects of NF-κB dynamic behaviour as a new potential biomarker for personalized medicine in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP04: Inflammatory Bowel Disease (IBD) and Solid Organ Transplantation. Natural history of pre-existing and de novo IBD patients. (EITOS study of GETECCU)
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP04: Single cell RNA sequencing identifies distinct intestinal inflammation patterns between primary sclerosing cholangitis-associated colitis and Ulcerative Colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP04: Single cell RNA sequencing reveals a potential role for IFNγ in priming circulating monocytes for intestinal inflammatory function in Crohn's Disease.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP04: The ability of epithelial regeneration is reduced in the Crohn’s disease patient-derived organoids, especially in TNF-α enriched condition
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP05 Perioperative Dietary Therapy in inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP050: Influence of disease location on vedolizumab efficacy in inflammatory bowel disease: a real-life multicentre experience
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP050: Serum proteomic analysis defines novel circulating inflammatory markers for Crohn's disease and response to anti-TNF therapy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP050: The efficacy of vedolizumab by disease activity and prior tumour necrosis factor-alpha antagonist failure in patients with ulcerative colitis or Crohn’s disease: post-hoc analyses from the GEMINI 1 and GEMINI 2 studies
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP051: Response and remission rates with up to 3 years of vedolizumab treatment in patients with ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP051: Serological biomarkers of tissue turnover can early identify responders to infliximab in Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP051: Shorter disease duration is associated with higher response rates to vedolizumab in Crohn’s disease but not ulcerative colitis: a multi-centre consortium analysis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP052: Molecular response to ustekinumab in moderate-to-severe Crohn's disease by serum protein and biopsy gene expression analysis: results from Ustekinumab phase 3 studies
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP052: Ozanimod induces histological response and remission: results from the TOUCHSTONE study, a randomised, double-blind, placebo-controlled trial of ozanimod, an oral S1P receptor modulator, in moderate-to-severe ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP052: Vedolizumab vs. ustekinumab for Crohn’s disease: comparative effectiveness in a real-life observational cohort study (ICC case series)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP053: Effects of oral tofacitinib on patient-reported outcomes in patients with moderate-to-severe Crohn’s disease: results of 2 Phase 2b randomised placebo-controlled trials
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP053: Impact of concomitant immunomodulator use on vedolizumab effectiveness: a multicentre consortium propensity score-matched analysis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP053: The fecal microbiome as a tool for monitoring and predicting response outcomes in ustekinumab-treated, anti-TNFα refractory Crohn's disease patients: results from the CERTIFI study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM